Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

Launched by DUKE UNIVERSITY · Jul 24, 2024

Keywords

ClinConnect Summary

The LAmB-FAST trial is a research study that aims to find better ways to treat a fungal infection called talaromycosis, particularly in people living with HIV. This study will test two main ideas: first, whether a single dose of a medication called liposomal amphotericin B (LAmB) is more effective than a longer treatment with a different version of the same drug. Second, it will explore if adding another medication called flucytosine (5FC) improves the treatment outcomes compared to using LAmB alone. Additionally, the study will look into whether stopping a maintenance medication based on HIV viral load is as effective as the current method that relies on a specific immune cell count.

To participate in this trial, you need to be an adult (18 years or older) who is living with HIV and has been diagnosed with talaromycosis. However, certain conditions may prevent you from joining, such as having a severe allergy to the study medications, a low white blood cell count, or being pregnant. If you qualify, you can expect to receive either one of the treatment options and will be monitored closely throughout the study to see how well the treatments work. This trial is not yet recruiting participants, but it aims to improve future treatment guidelines for this serious condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • HIV infected adults (age greater or equal to 18), on ART or no ART
• • Definitive talaromycosis confirmed by microscopy, histology, or culture
• Exclusion Criteria:
• • Known severe allergy to AmB or 5FC
• • Absolute neutrophil count \<500 cells
• • Concurrent cryptococcal or TB meningitis
• • Received \> 2 doses of DAmB
• • Pregnancy